Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers

被引:78
|
作者
Maroun, RG
Gayet, S
Benleulmi, MS
Porumb, H
Zargarian, L
Merad, H
Leh, H
Mouscadet, JF
Troalen, FR
Fermandjian, S
机构
[1] Inst Gustave Roussy, UMR 8532 CNRS, Dept Biol & Pharmacol Struct, F-94805 Villejuif, France
[2] Inst Gustave Roussy, UMR 8532 CNRS, Lab Physiochim & Pharmacol Macromol Biol, F-94805 Villejuif, France
[3] Inst Gustave Roussy, UMR 8532 CNRS, Lab Microchim & Immunol Mol, Dept Biol, F-94805 Villejuif, France
[4] Univ St Joseph, CST Mar Roukos, Fac Sci, Dept Sci Vie & Terre, Beirut, Lebanon
关键词
D O I
10.1021/bi011328n
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Integration of HIV-1 genome into host cell chromosome is mediated by viral integrase (IN). The IN catalytic core (CC, IN50-212) dimerizes through mutual interactions of its alpha1 and alpha5 helices. Peptides INH1 and INH5 reproducing these helix sequences strongly inhibited IN. For instance, an IC50 of 80 nM was determined for INH5 in integration assays using wild-type IN (wtIN). In size exclusion chromatography, INH1 and INH5 perturbed the association-dissociation equilibrium of both dmIN (IN1-288/F185K/C280S) and CC, leading to monomers as surviving species, while in circular dichroism, binding of peptides to dmIN altered the protein conformation. Thus, enzyme deactivation, subunit dissociation, and protein unfolding are events which parallel one another. The target of INH5 in the enzyme was then identified. In fluorescence spectroscopy, C-0.5 values of 168 and 44 nM were determined for the binding affinity of INH5 to IN and CC, respectively, at 115 nM subunit concentration, while interaction of INH5 with INH1 was found stronger than interaction of INH5 with itself (23 times larger in term of dissociation constants). These results strongly suggested that the alpha1 helix is the privileged target of INH5. The latter could serve as a lead for the development of new chemotherapeutic agents against HIV-1.
引用
收藏
页码:13840 / 13848
页数:9
相关论文
共 50 条
  • [21] Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
    Meixenberger, Karolin
    Yousef, Kaveh Pouran
    Somogyi, Sybille
    Fiedler, Stefan
    Bartmeyer, Barbara
    von Kleist, Max
    Kuecherer, Claudia
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 157 - 157
  • [22] Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds
    Maes, M.
    Levin, A.
    Hayouka, Z.
    Shalev, E.
    Loyter, A.
    Friedler, A.
    JOURNAL OF PEPTIDE SCIENCE, 2010, 16 : 163 - 163
  • [23] Peptide inhibitors of HIV-1 integrase: From mechanistic studies to improved lead compounds
    Maes, Michal
    Levin, Aviad
    Hayouka, Zvi
    Shalev, Deborah E.
    Loyter, Abraham
    Friedler, Assaf
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (22) : 7635 - 7642
  • [24] ORGN 915-Hydrocarbon stapled interfacial peptide inhibitors of HIV-1 integrase
    Hershberger, Stefan J.
    Chmielewski, Jean
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [25] Update on HIV integrase inhibitors for the treatment of HIV-1 infection
    Max, Blake
    FUTURE VIROLOGY, 2019, 14 (10) : 693 - 709
  • [26] Novel furocoumarins as potential HIV-1 integrase inhibitors
    Olomola, Temitope O.
    Mosebi, Salerwe
    Klein, Rosalyn
    Traut-Johnstone, Telisha
    Coates, Judy
    Hewer, Raymond
    Kaye, Perry T.
    BIOORGANIC CHEMISTRY, 2014, 57 : 1 - 4
  • [27] Hydrazide-containing inhibitors of HIV-1 integrase
    Zhao, H
    Neamati, N
    Sunder, S
    Hong, HX
    Wang, SM
    Milne, GWA
    Pommier, Y
    Burke, TR
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (06) : 937 - 941
  • [28] Novel, small molecule inhibitors of HIV-1 integrase
    Wu, J. J.
    Milot, G.
    Dandache, S.
    Gouveia, K.
    Xiao, Y.
    Yelle, J.
    Sevigny, G.
    Dubois, A.
    Tian, B.
    Perron, V.
    Herbart, D.
    Stranix, B. R.
    ANTIVIRAL THERAPY, 2007, 12 : S8 - S8
  • [29] Hydrazide-containing inhibitors of HIV-1 integrase
    Zhao, H
    Neamati, N
    Sunder, S
    Hong, HX
    Milne, GW
    Pommier, Y
    Burke, TR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 282 - MEDI
  • [30] Methylenebysphosphonates as new class of HIV-1 integrase inhibitors
    Anisenko, A.
    Agapkina, J.
    Korolev, S.
    Yanvarev, D.
    Kochetkov, S.
    Gottikh, M.
    FEBS JOURNAL, 2013, 280 : 365 - 366